10-Q · May 13, 2026
Inovio Pharmaceuticals reported a challenging Q1 2026, with no revenue generated compared to $65,000 in Q1 2025, and a widening loss per share of $0.87 versus a loss of $0.51 in the prior year. Operating expenses…
Earnings analysis · 10-Q
INO earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q text does not include the financial statements or MD&A results needed to assess Q2 revenue, margins, EPS, cash flow, working capital, or segment performance. The principal financial signal is…
Read full summary
The supplied 10-Q text does not include the financial statements or MD&A results needed to assess Q2 revenue, margins, EPS, cash flow, working capital, or segment performance. The principal financial signal is significant liquidity stress: $36.7 million of cash, cash equivalents and short-term investments against a $1.8 billion accumulated deficit, with substantial doubt about continuing as a going concern and funding projected only into late first quarter 2027. Regulatory and execution risk has increased following approval of PAPZIMEOS for the same RRP indication, while litigation and substantial potential dilution further weigh on the outlook.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls remained effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no changes in internal control over financial reporting during the quarter that materially affected, or were reasonably likely to materially affect, controls.
-
Cash runway extends into early 2027
The company reported cash, cash equivalents and short-term investments of $36.7 million as of June 30, 2026 and expects these resources to fund planned operating expenses and capital expenditures into late first quarter 2027, including a potential INO-3107 launch if approved.
-
Regulatory designations support INO-3107
INO-3107 has received both Orphan Drug Designation and breakthrough therapy designation from the FDA, while the company is pursuing accelerated approval for recurrent respiratory papillomatosis.
-
Prior device issue reportedly addressed
The company states that it has rectified a manufacturing issue in the single-use administration component of the CELLECTRA 5PSP device that had delayed the confirmatory trial and INO-3107 BLA submission.
What to watch
-
Going-concern and funding risk
The company states that it does not have sufficient working capital to fund planned operations for the next 12 months and that substantial doubt exists about continuing as a going concern. At June 30, 2026, accumulated deficit was $1.8 billion and cash, cash equivalents and short-term investments were $36.7 million; management's runway estimate extends only into late first quarter 2027.
-
Material dilution from July offering
The July 2026 Offering issued 21,052,632 common shares and warrants to purchase up to 42,105,264 shares, with the warrant amount increasing to up to 48,421,052 shares after the underwriter exercised its option. Further issuance or exercise could substantially dilute existing stockholders.
-
New approved competitor raises bar
The FDA approved PAPZIMEOS for recurrent respiratory papillomatosis, and the company anticipates that INO-3107 may not qualify for accelerated approval unless it demonstrates a clinically meaningful benefit over existing therapies, including PAPZIMEOS.
-
Multiple litigation matters remain active
A shareholder class action filed February 6, 2026 alleges misleading statements about the FDA submission and review timeline for INO-3107; five shareholder derivative complaints had been filed by July 22, 2026. The VGXI supply litigation is scheduled for a seven-day trial beginning October 13, 2026.
-
Manufacturing and supply-chain exposure
The company relies on single-source suppliers and previously identified a manufacturing issue that delayed the INO-3107 confirmatory trial and BLA submission. It also states that it previously relied on VGXI, which became unable to produce required plasmids because of insufficient manufacturing capacity.
-
Tariff and geopolitical exposure
The 10-Q identifies potential supply-chain and financing pressure from tariffs and trade restrictions, noting that the principal suppliers of critical raw materials and the INO-3107 active pharmaceutical ingredient manufacturer are located in Europe, while some clinical materials and device components may be manufactured in China.
Management's outlook
No numeric revenue or EPS guidance was provided in the supplied 10-Q text. Management states that cash, cash equivalents and short-term investments as of August 12, 2026 are expected to fund planned operating expenses and capital expenditures through a potential INO-3107 launch, if approved, and into late first quarter 2027.
Earlier filings 4
10-K · March 12, 2026
INOVIO’s 2025 Form 10-K highlights regulatory progress for lead candidate INO-3107 (BLA accepted with a PDUFA target date of October 30, 2026) and supportive multi‑year clinical durability signals, but the company…
10-Q · November 14, 2024
Inovio reported Q3 2024 revenue of $0 and GAAP diluted loss per share of $(0.89). The company recorded a quarterly net loss of $25,165,478 and ended the quarter with cash and short-term investments of approximately…
10-Q · August 8, 2024
Inovio reported Q2 2024 revenue of $100,762 and a net loss of $32.24M (EPS $(1.19)). Revenue declined materially year-over-year (from $225,971 in Q2 2023) while operating and net losses improved modestly vs. the…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.